Inner Mongolia Furui Medical Science Co., Ltd.

300049 · XSHE · Biotechnology · China

Fcf Positive 3yGross Profit MarginProfitable 3yReturn 1yRevenue Growing 3y

Market Capitalization14.27B CNY

Trailing P/E113.08 CNY

52-Week Change36.61 CNY

Beta-0.4000 CNY

Inner Mongolia Furui Medical Science Co., Ltd. is a prominent player in the biotechnology and pharmaceuticals industry. The company's primary function is focused on the research, development, and marketing of medical and pharmaceutical products. Particular emphasis is placed on innovative therapies and health solutions, contributing to advancements in medical science and patient care. With its significant operations centered in China, Inner Mongolia Furui Medical Science Co., Ltd. has established a robust presence in the domestic healthcare sector. It deals with various activities, including the production of biopharmaceuticals, which are integral to addressing unmet medical needs and improving health outcomes. The company leverages its expertise in biotechnology to contribute to the production of cutting-edge therapeutic products. In the financial markets, Inner Mongolia Furui Medical Science Co., Ltd. is recognized for its impact on the regional healthcare landscape. Its efforts in research and development, especially in biopharmaceuticals, underscore its role as a key entity fostering innovation and growth within the healthcare industry.

Industry

Biotechnology

Healthcare sector · China

Stories

Structural patterns identified in Inner Mongolia Furui Medical Science Co., Ltd.

Screen for these patterns

Key Metrics

Market Capitalization

14.27BCNY

NormalMar 18, 2026

Trailing P/E

113.08CNY

AboveNormalMar 18, 2026

Revenue (TTM)

1.47BCNY

NormalMar 18, 2026

Coordination

Placeholder CorpCoordination

Example HoldingsCoordination

Sample IncCoordination

Supply Chain

Vaccine Supply Chain

The vaccine supply chain is shaped by three structural constraints that most manufacturing industries never encounter: cold chain integrity requires unbroken refrigeration from manufacturing to injection — with some products requiring ultra-cold storage at -70°C, biological manufacturing variability means vaccines are grown in living systems where yields fluctuate batch to batch and cannot be precisely controlled, and regulatory lot release requires every batch to be independently tested and approved before distribution — a process that takes weeks and cannot be skipped or parallelized.